1 DNA Way
South San Francisco
About Genentech, Inc.
Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.
On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.
Connect with us via Social Media:
CEO: Ian T. Clark
CEO: Ed Harrington
Chief Medical Officer: Sandra J. Horning, MD
Chief Compliance Officer: Frederick C. Kentz, III
Please click here for clinical trial information.
Living 10 Years in the Future
1020 articles with Genentech, Inc.
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Curis, Inc. today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development.
Genentech’s hemophilia treatment Hemlibra continues to demonstrate its efficacy in treating patients. New late-stage data presented at World Federation of Hemophilia 2018 World Congress shows the drug significantly reduced treated bleeds in a broad patient population in two separate studies.
Genentech’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III HAVEN 3 Study in Hemophilia A without Factor VIII Inhibitors
– In a subset of patients in the HAVEN 3 study who previously received factor VIII prophylaxis, the standard of care, HEMLIBRA reduced bleeds by 68 percent compared to their prior therapy – – Phase III HAVEN 4 results showed HEMLIBRA every four weeks provides clinically meaningful control of bleeding in people with or without factor VIII inhibitors –
coreHEM Publishes Core Outcome Set for Hemophilia Clinical Trials; Prepares to Launch Next Phase of Work
The coreHEM initiative has announced the publication of a core outcome set for clinical trials of gene therapy in hemophilia.
Genentech, released follow-up data from its Phase III ALEX trial comparing its Alecensa (alectinib) to Pfizer’s Xalkori (crizotinib) in late-stage non-small cell lung cancer (NSCLC).
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
Genentech, has terminated its research program with Ames, Iowa-based NewLink Genetics.
The U.S. Food and Drug Administration (FDA) approved Pfizer’s Retacrit (epoetin alfa-epbx), a biosimilar to Amgen’s Epogen/Procrit (epoetin alfa). The drugs treat anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in HIV patients.
Genentech to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in People With Hemophilia A at the World Federation of Hemophilia 2018 World Congress
Data include results from HAVEN 3 study in people with hemophilia A without factor VIII inhibitors and HAVEN 4 study in people with hemophilia A with or without factor VIII inhibitors
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age and older. Actemra can be given alone or in combination with methotrexate (MTX) in patients with PJIA
AstraZeneca and its biologics research-and-development arm, MedImmune, indicated that its Fasenra (benralizumab) did not meet its primary endpoint in patients with moderate to very severe COPD.
Changes continue at the c-suite level of GlaxoSmithKline. This week another high profile executive, Chief Financial Officer Simon Dingemans announced he will retire from GSK in 2019.
Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.
Genentech reported that its Phase III IMblaze370 trial of Tecentriq (atezolizumab) and Cotellic (cobimetinib) for difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) did not meet its primary endpoint of overall survival (OS) compared to Bayer’s Stivarga (regorafenib).
Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer
The study did not meet its primary endpoint of improving overall survival versus regorafenib. Results will be submitted for presentation at an upcoming medical meeting.
5/9/2018Lodo Therapeutics, based in New York, formed a strategic drug discovery collaboration with Genentech, a Roche company, in a deal potentially worth more than $1 billion.
Collaboration provides Genentech with access to Lodo Therapeutics’ proprietary metagenomics-based natural products drug discovery platform Lodo to receive up to $969 million in upfront fees and milestone payments
The U.S. Food and Drug Administration (FDA) granted Genentech’s Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) Priority Review for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
As we get closer to seeing the U.S. Food and Drug Administration green light the first gene therapy for hemophilia, analysts estimate that the cost of the probable one-time treatment could have a whopping price-tag of $1.5 million.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.